The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings

The PI3K/mTOR inhibitor Gedatolisib eliminates dormant breast cancer cells in organotypic culture, but fails to prevent metastasis in preclinical settings

Dormant, disseminated tumor cells (DTCs) are thought to be the source of breast cancer metastases several years or even decades after initial treatment. To date, a selective therapy that leads to their elimination has not been discovered. While dormant DTCs resist chemotherapy, evidence suggests tha...

Full description

Bibliographic Details
Main Authors: Ryann E. Shor, Jinxiang Dai, Sun‐Young Lee, Laura Pisarsky, Irina Matei, Serena Lucotti, David Lyden, Mina J. Bissell, Cyrus M. Ghajar
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Molecular Oncology
Subjects:
breast cancer
disseminated tumor cell dormancy
gedatolisib
integrin‐β1
metastasis
phosphatidylinositol 3‐kinase/PI3K
Online Access:https://doi.org/10.1002/1878-0261.13031

Internet

https://doi.org/10.1002/1878-0261.13031

Similar Items